Healthcare Industry News:  Teva Pharma 

Devices Personnel

 News Release - January 17, 2012

Aerocrine appoints pulmonologist Paul Dorinsky, M.D., as medical director, North America

SOLNA, Sweden--(Healthcare Sales & Marketing Network)-- Aerocrine AB (OMX Nordic Exchange: AERO)(STO:AEROB) today announced that they have strengthened their medical team by adding former Teva R&D VP, Dr. Paul Dorinsky. Paul joins Aerocrine as medical director, North America.

Paul is board certified in pulmonary and critical care medicine. He spent 15 years on faculty at The Ohio State University College of Medicine before joining the industry in 1997. Most recently, Dr. Dorinsky served as vice president, global respiratory R&D, at Teva Pharmaceuticals. He has also worked at Boehringer Ingelheim and GlaxoSmithKline, where he spent 10 years in various leadership positions in respiratory clinical development and medical affairs.

Based in the U.S., Dr. Dorinsky will have the responsibility of leading clinical development and medical affairs for North America. He will report directly to Kathy Rickard, M.D., chief medical officer.

“As a nationally recognized expert in pulmonary disease, Dr. Dorinsky brings extensive clinical knowledge in the areas of asthma management and airway inflammation,” says Dr. Rickard. “His deep experience in clinical trial design and commercialization for respiratory products is invaluable, and I am pleased to welcome Dr. Dorinsky to Aerocrine’s medical team.”

Asthma is a chronic inflammatory disease of the airways that affects more than 300 million people worldwide, many of whom are children. FeNO is a marker of the underlying airway inflammation associated with asthma, and Aerocrine has developed a method to quickly measure this inflammation. Using NIOX MINO®, a simple, quantitative and cost-effective test, physicians can obtain information about the patient’s airway inflammation within two minutes.

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Actand/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on January the 17th 2011.

Source: Aerocrine

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.